Harnessing Innate and Adaptive Immune Responses to Cure Disease
Building upon the long-standing observation of tumor regression in the setting of bacterial infection, we have developed a unique and patented approach designed to exploit bacteria’s natural ability to fully engage the human immune system and cure disease. Our novel insights have enabled us to create proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models to date.
Latest Press Release
June 9, 2022
NEW YORK (June 9, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022 at 2:30 p.m. ET in New York City. read more →